Stocktoria
Harmony Biosciences Holdings, Inc. HRMY
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-08-19
Harmony Biosciences Holdings, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $868.5M | $714.7M | $582.0M | $437.9M | $305.4M | $159.7M | $6.0M |
| Gross profit | $670.1M | $557.9M | $460.8M | $354.4M | $249.9M | $132.0M | $4.4M |
| R&D expense | $189.6M | $145.8M | $76.1M | $70.9M | $30.4M | $19.4M | $69.6M |
| Operating income | $208.5M | $190.8M | $192.0M | $120.2M | $87.5M | $17.0M | -$145.9M |
| Interest expense | — | — | $23.8M | $18.8M | $24.2M | — | — |
| Income tax | $56.4M | $46.3M | $44.5M | -$76.8M | $2.8M | — | — |
| Net income | $158.7M | $145.5M | $128.9M | $181.5M | $34.6M | -$36.9M | -$152.0M |
| EPS (diluted) | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 | $-2.48 | $-24.07 |
| Operating cash flow | $348.2M | $219.8M | $219.4M | $144.5M | $98.6M | -$3.0M | -$75.4M |
| Free cash flow | $347.9M | $218.7M | $219.1M | $144.3M | $98.3M | -$3.0M | -$75.6M |
| Cash & equivalents | $752.5M | $453.0M | $311.7M | $243.8M | $234.3M | $228.6M | $24.5M |
| Inventory | $5.4M | $7.2M | $5.4M | $4.3M | $4.4M | $3.8M | $1.1M |
| Total assets | $1.3B | $999.2M | $811.4M | $673.9M | $433.4M | $427.1M | $106.7M |
| Total liabilities | $401.4M | $340.0M | $344.5M | $271.0M | $246.9M | $329.9M | $118.3M |
| Shareholders' equity | $870.2M | $659.2M | $467.0M | $402.8M | $186.5M | $97.2M | -$422.9M |
Growth · year-over-year · Revenue CAGR 129.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +21.5% | +22.8% | +32.9% | +43.4% | +91.2% | +2564.6% | — |
| Net income growth | +9.1% | +12.9% | -29.0% | +424.5% | — | — | — |
| EPS growth | +8.0% | +17.8% | -28.3% | +412.1% | — | — | — |
| Free cash flow growth | +59.1% | -0.2% | +51.8% | +46.9% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.